Cimzia Prevented Disease Progression, Inflammation in Axial SpA, Phase 3 Trial Shows
Treatment with Cimzia (certolizumab pegol) decreased long-term inflammation and disease progression in patients with axial spondyloarthritis (axSpA), an analysis of Phase 3 trial data shows. The results appeared in the study, “Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial…